Senores Pharmaceuticals Acquires Apnar Pharma – Analyzed

Senores Pharmaceuticals has bought Apnar Pharma, another drug company. This means Senores now owns all of Apnar Pharma’s stock. Apnar Pharma makes common medicines (called ‘generics’) and has approval from important health groups like the FDA in America, the MHRA in the UK, and Health Canada.

• Senores paid roughly Rs 91 crore to acquire Apnar Pharma.
• The deal happened in two payments over six years.
• 75% was bought now, 25% later, by March 2027.
• Rs 76 crore covered debt and facility liabilities.
• Rs 15 crore will be paid in cash for the purchase.
• Apnar Pharma’s sales were Rs 14.21 crore last year.

Senores is a big, international drug company. They create and sell medicines all over the world, mostly in the United States, Canada, and other countries where medicines are strictly controlled.

Recently, Senores’ profits went up a lot – they increased by 152% compared to the same time last year. Their sales also increased significantly, jumping 56% year-on-year.

The stock price for Senores went up slightly – it increased by 0.17% to Rs 816.90 on the BSE stock exchange.

This acquisition strengthens Senores’ position in the generic drug market globally.